FDA Approves a New PARP Inhibitor for BRCA-mutant Breast Cancer

In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

Understanding Inherited Breast Cancer

Breast cancer is the most commonly diagnosed cancer in the United States. In 2018, 266,120 women and 2,550 men are expected to receive the news that they have the disease, according to National Cancer Institute data.

Inherited mutations in the BRCA1 and BRCA2 genes account for between 5 percent and 10 percent of breast cancers in U.S. women and between 5 percent and 20 percent of breast cancers in U.S. men. For women who undergo genetic testing and learn that they have inherited a BRCA1/2 mutation before they receive a breast cancer diagnosis there are ways to reduce their risk of going on to develop the disease.

Read More

Can Artificial Intelligence Help Reduce False-positive Mammograms?

In a study published in the AACR’s journal Clinical Cancer Research, a team of scientists from the University of Pittsburgh discuss yet another area of cancer research where artificial intelligence (AI) can potentially solve a decades-long problem: false-positive results and high patient recall rates from breast cancer screening mammography.

Read More

FDA Approves First Targeted Therapeutic for BRCA-mutant Breast Cancer

On Friday, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic olaparib (Lynparza) for treating certain patients with metastatic, HER2-negative breast cancer. The FDA also granted marketing authorization for a test to identify those patients eligible to receive olaparib: patients with an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.

Read More

SABCS Marks 40 Years

Kent Osborne, MD, a codirector of SABCS, wrote a guest post for Cancer Research Catalyst in 2015 that details the symposium’s growth. We’re happy to present it again. Check back with Cancer Research Catalyst frequently for updates from SABCS, which will take place Dec. 5-9.

Read More

Treating DNA Repair-deficient Breast Cancers

Several clinical trials are underway in which PARP inhibitors are being tested in breast cancers, mostly triple-negative breast cancers, because they often harbor BRCA mutations and DNA repair deficiencies. Emerging studies show that the benefit of PARP inhibitors could extend beyond breast cancers with germline BRCA mutations.

Read More

FDA Approves New Treatment Option for Breast Cancer

Last week, the U.S. Food and Drug Administration (FDA) provided some good news for the breast cancer community just days before the start of breast cancer awareness month when it added a new molecularly targeted therapeutic to the armamentarium for oncologists treating patients with breast cancer: abemaciclib (Verzenio).

Read More

News from the Cancer Centers: How DCIS Becomes Invasive Breast Cancer

Earlier this year, a study published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR), explored the question of how preinvasive breast tumors become invasive. The study’s lead author, Kornelia Polyak, MD, PhD, discussed the findings in an article published by Inside the Institute, a publication of Dana-Farber Cancer Institute.

Read More

FDA Approves a New HER2-targeted Therapeutic for Breast Cancer

Earlier this week, the U.S. Food and Drug Administration (FDA) approved a new molecularly targeted therapeutic called neratinib (Nerlynx) for treating certain patients with HER2-positive breast cancer. Specifically, the FDA approved neratinib for reducing disease recurrence in patients with early-stage HER2-positive breast cancer who have completed postsurgery (adjuvant) treatment with trastuzumab (Herceptin) and whose disease has not progressed.

Read More

New Therapeutic Approved by FDA to Treat Breast Cancer

Earlier this week, the U.S. Food and Drug Administration approved the molecularly targeted therapeutic ribociclib (Kisqali) for use in combination with any aromatase inhibitor for initial treatment of postmenopausal women with a hormone receptor (HR)–positive, HER2-negative, advanced breast cancer.

Read More